MX2020007072A - Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma. - Google Patents
Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma.Info
- Publication number
- MX2020007072A MX2020007072A MX2020007072A MX2020007072A MX2020007072A MX 2020007072 A MX2020007072 A MX 2020007072A MX 2020007072 A MX2020007072 A MX 2020007072A MX 2020007072 A MX2020007072 A MX 2020007072A MX 2020007072 A MX2020007072 A MX 2020007072A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- fusion protein
- cells
- pharmaceutical composition
- fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 title abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005965 immune activity Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180110698 | 2018-09-17 | ||
| KR20190001867 | 2019-01-07 | ||
| US201962832013P | 2019-04-10 | 2019-04-10 | |
| KR20190053436 | 2019-05-08 | ||
| PCT/KR2019/011928 WO2020060122A1 (ko) | 2018-09-17 | 2019-09-16 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007072A true MX2020007072A (es) | 2020-11-11 |
Family
ID=69887592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007072A MX2020007072A (es) | 2018-09-17 | 2019-09-16 | Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11492384B2 (enExample) |
| EP (2) | EP4403635A3 (enExample) |
| JP (2) | JP7085644B2 (enExample) |
| KR (2) | KR102201086B1 (enExample) |
| CN (2) | CN118725141A (enExample) |
| AU (1) | AU2019343850B2 (enExample) |
| CA (1) | CA3086486A1 (enExample) |
| CL (1) | CL2020001872A1 (enExample) |
| DK (1) | DK3715367T3 (enExample) |
| ES (1) | ES2985387T3 (enExample) |
| FI (1) | FI3715367T3 (enExample) |
| HU (1) | HUE068059T2 (enExample) |
| IL (1) | IL275592B (enExample) |
| MX (1) | MX2020007072A (enExample) |
| PE (1) | PE20201418A1 (enExample) |
| PH (1) | PH12020551026A1 (enExample) |
| PL (1) | PL3715367T3 (enExample) |
| PT (1) | PT3715367T (enExample) |
| SG (1) | SG11202005873QA (enExample) |
| TW (2) | TWI755630B (enExample) |
| WO (1) | WO2020060122A1 (enExample) |
| ZA (1) | ZA202003645B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3026474A1 (en) * | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| KR102201086B1 (ko) * | 2018-09-17 | 2021-01-11 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
| JP7543404B2 (ja) * | 2019-11-20 | 2024-09-02 | ジーアイ・セル・インコーポレイテッド | Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法 |
| PL4063491T3 (pl) * | 2019-11-20 | 2025-03-31 | Gi Cell, Inc. | Kompozycja do hodowli komórek naturalnych zabójców i sposób otrzymywania komórek naturalnych zabójców z jej zastosowaniem |
| JP7488337B2 (ja) * | 2019-11-27 | 2024-05-21 | ジーアイ・セル・インコーポレイテッド | Ｉｌ－２タンパク質及びｃｄ８０タンパク質を含む融合タンパク質及びｎｋ細胞を含む抗癌治療用組成物 |
| US20230014358A1 (en) * | 2019-11-27 | 2023-01-19 | Gi Cell, Inc. | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein |
| CN115989238A (zh) * | 2020-03-18 | 2023-04-18 | Gi医诺微新 | 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途 |
| PL4122447T3 (pl) | 2020-03-18 | 2025-11-24 | Gi Innovation, Inc. | Preparat białka fuzyjnego zawierający białka il-2 i cd80 |
| WO2021187922A1 (ko) | 2020-03-18 | 2021-09-23 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 |
| US11746137B2 (en) * | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
| US20230235011A1 (en) * | 2020-05-25 | 2023-07-27 | Beijing Beyond Biotechnology Co., Ltd | Fc-cd80 fusion protein and conjugates thereof and their uses |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| WO2022005174A1 (ko) * | 2020-06-30 | 2022-01-06 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240043544A1 (en) * | 2020-12-08 | 2024-02-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| JP2024518013A (ja) * | 2021-03-10 | 2024-04-24 | イミュノウェイク インコーポレイテッド | 免疫調節分子及びその使用 |
| WO2022057696A2 (zh) * | 2021-09-08 | 2022-03-24 | 中南大学湘雅医院 | 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法 |
| KR20230168273A (ko) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| EP4545562A4 (en) | 2022-06-22 | 2025-10-01 | Gi Innovation Inc | FUSION PROTEIN COMPRISING AN ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF |
| TW202421176A (zh) | 2022-09-20 | 2024-06-01 | 南韓商Ｇｉ生物群系公司 | 植物乳桿菌菌株的組合療法以及使用其的癌症治療方法 |
| EP4591873A1 (en) * | 2022-09-20 | 2025-07-30 | Gi Biome Inc. | Combined therapy of lactobacillus plantarum strain, and cancer treatment method using same |
| CN115850436A (zh) * | 2022-10-14 | 2023-03-28 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2025063755A1 (ko) * | 2023-09-20 | 2025-03-27 | 주식회사 에스엘바이젠 | 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0119621A1 (en) * | 1983-03-21 | 1984-09-26 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Interleukin-2 |
| CN86104525A (zh) * | 1985-07-31 | 1987-02-25 | 武田药品工业株式会社 | 人类白细胞介素-2的分析方法和试剂 |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| GB9810999D0 (en) | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| JP2005507870A (ja) | 2001-08-13 | 2005-03-24 | ユニバーシティ・オブ・サザン・カリフォルニア | 低毒性のインターロイキン−２突然変異体 |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| CU23229A1 (es) | 2002-05-10 | 2007-09-26 | Ct Ingenieria Genetica Biotech | ANTAGONISTA QUIMéRICO ANTH1 |
| RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| FI2402754T4 (fi) * | 2006-03-06 | 2023-10-06 | Ei-kiinteärakenteisia rekombinantteja polymeerejä ja niiden käyttötapoja | |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| WO2009023270A2 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| EP2673294B1 (en) | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| WO2014144960A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Fc variants |
| MY193723A (en) | 2014-08-29 | 2022-10-27 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| BR112018008865A8 (pt) * | 2015-11-02 | 2019-02-26 | Five Prime Therapeutics Inc | polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CA3026474A1 (en) * | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| MX2019011770A (es) * | 2017-04-03 | 2020-01-09 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15. |
| KR102201086B1 (ko) * | 2018-09-17 | 2021-01-11 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
-
2019
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/ko active Active
- 2019-09-16 EP EP24175556.0A patent/EP4403635A3/en active Pending
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 AU AU2019343850A patent/AU2019343850B2/en active Active
- 2019-09-16 HU HUE19862449A patent/HUE068059T2/hu unknown
- 2019-09-16 PT PT198624496T patent/PT3715367T/pt unknown
- 2019-09-16 ES ES19862449T patent/ES2985387T3/es active Active
- 2019-09-16 PL PL19862449.6T patent/PL3715367T3/pl unknown
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/es unknown
- 2019-09-16 EP EP19862449.6A patent/EP3715367B1/en active Active
- 2019-09-16 DK DK19862449.6T patent/DK3715367T3/da active
- 2019-09-16 CN CN202410942368.3A patent/CN118725141A/zh active Pending
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/ja active Active
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/es unknown
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 CN CN201980025699.8A patent/CN111971295B/zh active Active
- 2019-09-16 FI FIEP19862449.6T patent/FI3715367T3/fi active
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/ko not_active Ceased
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-17 TW TW108133398A patent/TWI755630B/zh active
- 2019-09-17 TW TW110122590A patent/TWI824258B/zh active
-
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/es unknown
-
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/ko active Active
-
2022
- 2022-04-21 JP JP2022070213A patent/JP7569820B2/ja active Active
- 2022-08-01 US US17/878,703 patent/US12286464B2/en active Active
- 2022-08-01 US US17/878,664 patent/US12291555B2/en active Active
-
2025
- 2025-04-01 US US19/097,579 patent/US20250230212A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007072A (es) | Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma. | |
| MX2020003250A (es) | Composiciones sinegísticas de pesticidas y métodos para la entrega de ingredientes activos. | |
| MX2017003819A (es) | Macrociclos peptidomimeticos y formulaciones de los mismos. | |
| MX2025004779A (es) | Formulaciones de proteinas de fusion vegfr-fc | |
| PE20191555A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y enfermedades inmunes y autoinmunes | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| MX378790B (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| ECSP19018654A (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| MX2020005518A (es) | Mezclas no racemicas y usos de las mismas. | |
| NI201600149A (es) | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasa | |
| CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
| CL2022001382A1 (es) | Composición farmacéutica para el tratamiento de cáncer, que comprende inhibidor de punto de control | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| BR112016005417A8 (pt) | "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos" | |
| ZA202210024B (en) | Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| MX2018010836A (es) | Conformeros abiertos hla-b57. | |
| PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
| PE20210779A1 (es) | NUEVA FORMULACIOìN ESTABLE DE ALTA CONCENTRACIOìN PARA ANTICUERPOS ANTI-FXIa | |
| CL2018002900A1 (es) | Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos. | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. | |
| MX2018005350A (es) | Formulacion de combinacion de dosis fija, eflornitina y sulindaco. |